Document is current
Any future updates will be listed below
-
Authors
Martuliak, Igor https://orcid.org/0000-0002-6889-5416
Chvála, Ľuboš https://orcid.org/0000-0002-4479-5699
Ferenčík, Miroslav https://orcid.org/0000-0002-0943-8418
Fabián, Vratislav https://orcid.org/0000-0002-6390-0116
Slovák, Matěj https://orcid.org/0000-0003-2023-5862
-
Funding
Funding for this research was provided by:
REBOX THERAPY s.r.o. (14/2023)
- License Information
-
More Information
Article History
Received: 24 June 2025
Accepted: 30 July 2025
First Online: 3 September 2025
Declarations
:
: Matěj Slovák is a co-owner and Vratislav Fabián is the Person Responsible for Regulatory Compliance (PRRC) according to the Medical Directive Regulation (EU) 2017/745 of REBOX THERAPY s.r.o., manufacturer of the device Rebox-Physio 4. Other authors (Igor Martuliak, Ľuboš Chvála and Miroslav Ferenčík) have nothing to disclose.
: The randomized, double-blind, sham-controlled crossover trial was approved by the Ethics Committee of F. D. Roosevelt University Hospital with Policlinic, Banská Bystrica, Slovakia (approval no. 14/2023). The study was preregistered at ClinicalTrials.gov (ID: NCT05968274) on July 29, 2023. All procedures were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants, including consent for the use of indirect identifiers and publication of study results.
